RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RMD looks like a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has solid operating momentum, supportive analyst sentiment, and no major insider or hedge-fund red flags. It is not a low-risk bargain entry, but the data supports buying now rather than waiting. The best fit is a long-term accumulation position.
The technical picture is constructive. MACD histogram is positive and expanding, which supports upward momentum. Price at 209.07 is slightly below the recent resistance area near 211.83, while sitting above the pivot at 197.82 and above first support at 189.16. RSI_6 at 76.59 shows the stock is extended in the short term, but the moving averages are converging and the trend remains upward. Overall, the trend is bullish with near-term overextension, but not enough to override the broader positive setup. The recent pattern-based outlook also suggests modest upside over the next week and month.
["Q3 FY2026 revenue rose 10.8% year over year to $1.43 billion.", "Net income increased 9.2% and EPS grew 10.4%, confirming continued earnings growth.", "Goldman Sachs added ResMed to its APAC Conviction List and maintained a Buy rating.", "KeyBanc remains Overweight and sees continued OSA/CPAP patient demand strength.", "Average analyst price target of about $249.86 implies meaningful upside from the current price.", "No significant negative insider or hedge-fund trading trends were reported."]
["Morgan Stanley downgraded the stock to Equal Weight and cut its target, becoming more cautious on near-term earnings.", "Several firms lowered price targets recently, showing some moderation in expectations.", "Options positioning is put-heavy, with a put-call open interest ratio of 2.06.", "The stock is near short-term overbought levels after a strong recent run.", "No recent congress trading activity or influential buyer signal was reported."]
Latest quarter: Q3 FY2026. ResMed delivered strong growth with revenue up 10.8% to $1.43 billion, net income up 9.2% to $0.39 billion, and EPS up 10.4% to $2.74. This shows healthy top-line and bottom-line expansion, supporting a positive long-term growth profile.
Analyst sentiment remains mostly positive, though a bit more mixed than before. Recent notes include Goldman Sachs adding the stock to its conviction list, KeyBanc staying Overweight, Citi keeping Buy, and JPMorgan positive on the sleep apnea leadership story. On the cautious side, Morgan Stanley downgraded to Equal Weight and several firms trimmed price targets. Overall, Wall Street is still more bullish than bearish, but the average target has come down somewhat, reflecting near-term caution while preserving a constructive long-term view.
